A growing body of evidence suggests that metabolic events play essential roles in the development of
liver fibrosis. Immune response gene 1 (IRG1) catalyzes the generation of
itaconate, which function as a metabolic checkpoint under several pathological circumstances. In the present study, the hepatic level of IRG1 was determined in mice with
carbon tetrachloride (CCl4)-induced
liver fibrosis. And then the pathological significance of IRG1 and the pharmacological potential of
4-octyl itaconate (4-OI), a cell-permeable derivate of
itaconate, in
liver fibrosis were investigated in mice. The results indicated that the hepatic level of IRG1 was upregulated in mice with
liver fibrosis. CCl4-induced formation of fibrotic septa and deposition of
collagen was aggravated in IRG1 KO mice. IRG1 deletion also resulted in increased expression of
transforming growth factor beta 1 (TGF-β1), enhanced phosphorylation of Smad3, elevated level of alpha smooth muscle actin (α-SMA) and
hydroxyproline, which were associated with compromised activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated
antioxidant system and exacerbated oxidative stress. Interestingly, supplementation with 4-OI activated Nrf2 pathway, suppressed TGF-β1 signaling and attenuated fibrogenesis. Our data indicated that upregulation of IRG1 might function as a protective response during the development of
liver fibrosis, and 4-OI might have potential value for the pharmacological intervention of
liver fibrosis.